QTc prolongation and treatment of multidrug-resistant tuberculosis

被引：48

作者：

Harausz, E. ^{[1
]}

Cox, H. ^{[2
,3
]}

Rich, M. ^{[4
]}

Mitnick, C. D. ^{[5
]}

Zimetbaum, P. ^{[6
]}

Furin, J. ^{[1
]}

机构：

[1] Case Western Reserve Univ, TB Res Unit, Cleveland, OH 44106 USA

[2] Univ Cape Town, Div Med Microbiol, ZA-7700 Rondebosch, South Africa

[3] Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7700 Rondebosch, South Africa

[4] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA

[5] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA

[6] Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02215 USA

来源：

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE | 2015年 / 19卷 / 04期

关键词：

MDR-TB; ECG; QTc; TORSADES-DE-POINTES; EARLY BACTERICIDAL ACTIVITY; INTERVAL PROLONGATION; DIARYLQUINOLINE TMC207; DELAMANID OPC-67683; DRUG; SAFETY; RISK; PHARMACOKINETICS; FLUOROQUINOLONES;

D O I：

10.5588/ijtld.14.0335

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Electrocardiographic (ECG) monitoring is recommended for some of the new and re-purposed drugs used in the treatment of multidrug-resistant tuberculosis (MDR-TB), as these drugs have been shown to prolong the QTc interval. ECG monitoring is relatively new in the management of TB patients, and has several implications for programs and providers. This review discusses what is known about QTc prolongation and the medications currently being studied or used to treat MDR-TB, and discusses strategies for managing QTc prolongation in the context of treating such a serious infectious disease. It also reviews some major implications of ECG monitoring in the field, including interpretation of ECGs and QTc intervals, management of patients with prolonged QTc intervals, and contextualizing the risk of QTc prolongation for patients being treated for MDR-TB.

引用

页码：385 / 391

页数：7

共 50 条

[1] Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California
Katrak, Shereen
Lowenthal, Phil
Shen, Richard
True, Lisa
Henry, Leslie
Barry, Pennan
[J]. JOURNAL OF CLINICAL TUBERCULOSIS AND OTHER MYCOBACTERIAL DISEASES, 2021, 23
[2] Delamanid and QT prolongation in the treatment of multidrug-resistant tuberculosis
Gupta, Rajesh
Getter, Lawrence J.
Hafkin, Jeffrey
Wells, Charles D.
[J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2015, 19 (10) : 1261 - 1262
[3] Treatment of multidrug-resistant tuberculosis
Colebunders, R
Apers, L
Shamputa, IC
[J]. LANCET, 2004, 363 (9416): : 1240 - 1240
[4] TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS
COHN, DL
[J]. JOURNAL OF HOSPITAL INFECTION, 1995, 30 : 322 - 328
[5] Treatment Outcomes in Multidrug-Resistant Tuberculosis
Guenther, Gunar
Lange, Christoph
Alexandru, Sofia
Altet, Neus
Avsar, Korkut
Bang, Didi
Barbuta, Raisa
Bothamley, Graham
Ciobanu, Ana
Crudu, Valeriu
Danilovits, Manfred
Dedicoat, Martin
Duarte, Raquel
Gualano, Gina
Kunst, Heinke
de Lange, Wiel
Leimane, Vaira
Magis-Escurra, Cecile
McLaughlin, Anne-Marie
Muylle, Inge
Polcova, Veronika
Popa, Christina
Rumetshofer, Rudolf
Skrahina, Alena
Solodovnikova, Varvara
Spinu, Victor
Tiberi, Simon
Viiklepp, Piret
van Leth, Frank
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (11): : 1103 - +
[6] Surgery in the treatment of multidrug-resistant tuberculosis
Pomerantz, M
Brown, JM
[J]. CLINICS IN CHEST MEDICINE, 1997, 18 (01) : 123 - &
[7] Diagnosis and treatment of multidrug-resistant tuberculosis
Kang, Young Ae
[J]. JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2014, 57 (01): : 27 - 33
[8] Linezolid in the Treatment of Multidrug-Resistant Tuberculosis
Schecter, G. F.
Scott, C.
True, L.
Raftery, A.
Flood, J.
Mase, S.
[J]. CLINICAL INFECTIOUS DISEASES, 2010, 50 (01) : 49 - 55
[9] Treatment and Prevention of Multidrug-Resistant Tuberculosis
Ivan Bastian
Robert Colebunders
[J]. Drugs, 1999, 58 : 633 - 661
[10] Delamanid in the treatment of multidrug-resistant tuberculosis
Gupta, R.
Wells, C. D.
Hittel, N.
Hafkin, J.
Geiter, L. J.
[J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2016, 20 (12) : S33 - S37

← 1 2 3 4 5 →